Charles Laymon

Learn More
3035 Background: BAY 80-6946 is a potent and highly selective reversible pan-Class I PI3K inhibitor with anti-tumor activity in a panel of preclinical models. A phase I dose escalation multicenter study was initiated to determine the maximum tolerated dose (MTD), pharmacokinetics (PK), and pharmacodynamics (PD) in patients (pts) with advanced solid tumors.(More)
There are several artifacts unique to PET/CT imaging, with CT-based attenuation correction (AC) artifacts being among the most commonly reported. AC artifacts from calcified lymph nodes represent clinically significant and easily misinterpreted PET/CT artifacts that have received little attention in the literature. In this case series, we report three cases(More)
A project is underway to map die indoor radon potential for New York State at the township level. Through a detector distribution program the New York State Department of Health has a database of over 36,000 basement screening measurements. The address field for the indoor measurement data is being linked to latitude and longitude coordinates using data(More)